Active Ingredient History
Atenolol is a Beta-1 cardio-selective adreno-receptor blocking agent discovered and developed by ICI in 1976. Atenolol was launched in the market under the trade name Tenormin in 1976, and became the best-selling Beta-blocker in the world in the 1980s and 1990s. TENORMIN is indicated for the treatment of hypertension, to lower blood pressure; also for the long-term management of patients with angina pectoris and also is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Like metoprolol, atenolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension. Higher doses of atenolol also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles. Hypotensive mechanism of atenolol is very complex. Decrease in CO and inhibition of renin-angiotensin-aldosterone system may mainly be responsible for hypotension. It is likely that potassium retaining action of atenolol partly contributes to its hypotensive action. It is also hypothetized that renal kallikrein-kinin system may play a role in modulating the hypotensive action of atenolol. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Angina Pectoris (Phase 4)
Angina, Stable (Phase 4)
Aortic Aneurysm, Abdominal (Phase 4)
Arterial Pressure (Phase 4)
Atherosclerosis (Phase 4)
Atrial Fibrillation (Phase 4)
Blood Pressure (Phase 4)
Carotid Artery Diseases (Phase 4)
Cerebral Small Vessel Diseases (Phase 3)
Cerebrovascular Disorders (Phase 3)
Cognition Disorders (Phase 4)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 3)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Nephropathies (Phase 4)
Endothelium (Phase 4)
Essential Hypertension (Phase 4)
Exercise (Phase 4)
Fractures, Bone (Phase 3)
General Surgery (Phase 4)
Healthy Volunteers (Phase 4)
Heart Diseases (Phase 3)
Hemangioma (Phase 4)
Hyperlipidemias (Phase 2)
Hypertension ()
Hypertension, Pregnancy-Induced (Early Phase 1)
Hypertrophy, Left Ventricular (Phase 3)
Insulin Resistance (Phase 4)
Ischemic Stroke (Phase 4)
Marfan Syndrome (Phase 4)
Metabolic Syndrome (Phase 4)
Migraine Disorders (Phase 2)
Mitral Valve Stenosis (Phase 3)
Myocardial Infarction (Phase 4)
Myocardial Ischemia (Phase 3)
Neoplasms (Phase 4)
Obesity, Morbid (Early Phase 1)
Orthostatic Intolerance (Phase 1/Phase 2)
Pheochromocytoma (Phase 2)
Postural Orthostatic Tachycardia Syndrome (Phase 1/Phase 2)
Pre-Eclampsia (Early Phase 1)
Renal Dialysis (Phase 3)
Stress Disorders, Post-Traumatic (Phase 2)
Stroke (Phase 4)
Tachycardia (Phase 3)
Tuberculosis (Phase 4)
Vascular Diseases (Phase 3)
Vestibular Diseases (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
